Baseline characteristics of patients with locked-in syndrome
| Variables | All patients | SMT | EVT | P value |
| 120 | 28 | 92 | ||
| Age, years, median (IQR) | 67.00 (57.0–75.0) | 69.00 (60.0–75.0) | 65.00 (57.0–75.0) | 0.529 |
| Sex, male, n (%) | 91 (75.8) | 20 (71.4) | 71 (77.2) | 0.712 |
| SBP, mm Hg, (mean (SD) | 156 (25.0) | 162 (27.0) | 154 (24.0) | 0.117 |
| Smoking (%) | 39 (32.5) | 7 (25.0) | 32 (34.8) | 0.461 |
| NIHSS score at baseline, median (IQR) | 23.0 (18.0–27.0) | 23.0 (18.0–26.0) | 24.0 (19.0–27.0) | 0.443 |
| pc-ASPECTS at baseline, median (IQR) | 8.0 (7.0–9.0) | 8.0 (6.0–8.0) | 8.0 (7.0–9.0) | 0.131 |
| pc-CS score, median (IQR) | 5.0 (3.0–6.0) | 6.0 (3.0–8.0) | 5.0 (3.0–6.0) | 0.111 |
| BATMAN score, median (IQR) | 5.0 (3.0–6.0) | 6.0 (4.0–7.0) | 4.0 (3.0, 6.0) | 0.014 |
| GCS score, median (IQR) | 8.0 (6.0–9.0) | 8.0 (7.0–9.0) | 8.0 (6.0–9.0) | 0.536 |
| Medical history, n (%) | ||||
| Hypertension | 90 (75.0) | 22 (78.6) | 68 (73.9) | 0.803 |
| Hyperlipidemia | 40 (33.3) | 9 (32.1) | 31 (33.7) | 1 |
| Diabetes mellitus | 24 (20.0) | 5 (17.9) | 19 (20.7) | 0.957 |
| Atrial fibrillation | 18 (15.0) | 4 (14.3) | 14 (15.2) | 1 |
| Prestroke mRS score at baseline, n (%) | 0.075 | |||
| 0 | 109 (90.8) | 23 (82.2) | 86 (93.5) | |
| 1 | 7 (5.8) | 2 (7.1) | 5 (5.4) | |
| 2 | 4 (3.4) | 3 (10.7) | 1 (1.1) | |
| TIA | 1 (0.8) | 0 (0.0) | 1 (1.1) | 1 |
| Coronary heart disease | 14 (11.7) | 3 (10.7) | 11 (12.0) | 1 |
| Valvular heart disease | 3 (2.5) | 0 (0.0) | 3 (3.3) | 0.782 |
| Biochemical variables, median (IQR) | ||||
| Neutrophils, median (IQR) | 8.87 (6.96–12.20) | 8.35 (7.43–9.97) | 9.46 (6.94–12.37) | 0.506 |
| Triglycerides, mmol/L, median (IQR) | 1.17 (0.78–1.90) | 1.32 (0.84–1.96) | 1.15 (0.72–1.84) | 0.424 |
| Total cholesterol, mmol/L, median (IQR) | 4.64 (3.96–5.54) | 4.63 (4.00–4.84) | 4.68 (3.96–5.58) | 0.484 |
| Admission glucose, median (IQR) | 7.19 (6.12–8.51) | 6.95 (5.79–7.82) | 7.28 (6.30–8.97) | 0.263 |
| Cause of stroke, n (%) | 0.496 | |||
| LAA | 96 (80.0) | 23 (82.1) | 73 (79.3) | |
| CE | 19 (15.8) | 3 (10.7) | 16 (17.4) | |
| Other causes | 5 (4.2) | 2 (7.1) | 3 (3.3) | |
| General anesthesia, n (%) | NA | NA | 32 (34.8) | NA |
| Intravenous thrombolysis, n (%) | 28 (23.3) | 5 (17.9) | 23 (25.0) | 0.598 |
| Pneumonia, n (%) | 94 (78.3) | 22 (78.6) | 72 (78.3) | 1 |
| Time variables, min, median (IQR) | ||||
| OTI time, min | 246.0 (116.0–424.0) | 198.0 (87.0–534.0) | 260.0 (144.0–412.0) | 0.385 |
| OTT time, min | 283.0 (162.0–447.0) | 229.0 (115.0–584.0) | 298.0 (188.0–438.0) | 0.372 |
| OTP time, min | NA | NA | 363.0 (252.0–492.0) | NA |
| PTR time, min | NA | NA | 107.0 (80.0–151.0) | NA |
| LiS proportion, n (%) | 0.931 | |||
| Incomplete | 63 (52.5) | 14 (50.0) | 49 (53.3) | |
| Classic | 57 (47.5) | 14 (50.0) | 43 (46.7) | |
| Occlusion site, n (%) | 0.01 | |||
| Distal BA | 24 (20.0) | 2 (7.1) | 22 (23.9) | |
| Middle BA | 69 (57.5) | 23 (82.1) | 46 (50.0) | |
| Proximal BA | 27 (22.5) | 3 (10.7) | 24 (26.1) | |
| mTICI score 2b/3, n (%) | 72 (60.0) | NA | 72 (78.3) | NA |
| Type of endovascular treatment, n (%) | ||||
| Stent retriever thrombectomy | NA | NA | 65 (70.7) | NA |
| Aspiration | NA | NA | 5 (5.4) | NA |
| Balloon angioplasty and/or stenting | NA | NA | 10 (10.9) | NA |
| Intra-arterial medication and/or mechanical fragmentation | NA | NA | 12 (13.0) | NA |
| Combination | NA | NA | 63 (68.5) | NA |
OTP; onset to puncture; BA, basilar artery; BATMAN, Basilar Artery Treatment and Management ; CE, cardioembolism; EVT, endovascular treatment; GCS, Glasgow Coma Scale; IQR, interquartile rage; LAA, large artery atherosclerosis; LiS, locked in syndrome; mRS, modified Rankin Scale; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; OTI, onset to imaging; OTP, onset to puncture; OTT, onset to treatment; pc-ASPECTS, posterior circulation Alberta Stroke Program Early CT Score; pc-CS, posterior circulation collateral system score; PTR, puncture to recanalization; SBP, systolic blood pressure; SMT, standard medical treatment; TIA, transient ischemic attack.